

PU3375USW

30. (New) A method of treatment according to claim 28 wherein alosetron is in the form of its hydrochloride.

31. (New) A method of treatment of diarrhea-predominant female IBS which comprises administering an effective amount of a 5-HT₃ receptor antagonist or a pharmaceutically acceptable derivative thereof selected from the group consisting of granisetron, azasetron, tropisetron, ramosetron, ondansetron, leriisetron, (R) zacopride, cilansetron, itasetron, indisetron and dolasetron and pharmaceutically acceptable derivatives thereof.

32. (New) A method of treatment of diarrhea-predominant female IBS which comprises administering an effective amount of alosetron or a pharmaceutically acceptable derivative thereof.

33. (New) A method of treatment according to claim 32, wherein alosetron is in the form of its hydrochloride.

34. (New) A method of treatment of alternating constipation/diarrhea IBS which comprises administering an effective amount of a 5-HT₃ receptor antagonist or a pharmaceutically acceptable derivative thereof selected from the group consisting of granisetron, azasetron, tropisetron, ramosetron, ondansetron, leriisetron, (R) zacopride, cilansetron, itasetron, indisetron and dolasetron and pharmaceutically acceptable derivatives thereof.

35. (New) A method of treatment of alternating constipation/diarrhea IBS which comprises administering an effective amount of alosetron or a pharmaceutically acceptable derivative thereof.

36. (New) A method of treatment according to claim 35, wherein alosetron is in the form of its hydrochloride.

Remarks

Currently Claims 28-36 are pending. Claims 5-8 and 11-18 are canceled in favor of the newly added claims. Claims 19-27 are canceled subject to Applicants' right to file one or more divisional applications directed thereto.

20